Net revenue grew 20% year-over-year to SEK 6.5 billion, with EBIT margin improving to 4.1% and adjusted EBIT margin to 4.4%. Prescription sales surged, automation boosted efficiency, and the company completed a successful IPO, prioritizing reinvestment over dividends.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.